

Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)

<https://marketpublishers.com/r/B4354139CCAEN.html>

Date: October 2011

Pages: 152

Price: US\$ 1,200.00 (Single User License)

ID: B4354139CCAEN

Abstracts

With sales worth US\$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a marathon than a sprint. IMARC Group, one of the world's leading research and advisory firms, in its new report "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" finds that biosimilars in the US will soon represent a multi-billion dollar market as they would be posing stiff competition to as many as twenty biological molecules during 2011-2020.

Findings from the report suggest that the historical performance of Omnitrope cannot be taken as a benchmark to gauge the potential of pipeline biosimilars as market acceptance for each biosimilar class is expected to vary significantly from one another. The report expects that the competition between branded biological drugs and their biosimilar counterparts would be more of a brand-brand competition than a brand-generic competition. The high costs involved in the development and launch of biosimilars are expected to limit the number of players in this market. As a result, erosions in price and volume caused by biosimilars are likely to be lower compared to those created by small molecule generics.

IMARC's new report entitled "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.

Key Aspects Analyzed:

Evaluating the Current Market Landscape of Biosimilars:

Identification of currently marketed biosimilars and their historical performance

Identifying the reasons for the slow uptake of currently marketed biosimilars

Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilars

Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:

Analyzing historical time series data on price, volume and sales erosion in the US & Europe

Analyzing previous models and assumptions on price and volume erosion caused by biosimilars

Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics

Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes

Evaluating the Market Potential of Biosimilars Across Various Molecules:

Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eporex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbix), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).

Focus of the Analysis for Each Molecule:

Historical background and overview

Historical brand sales

Patent position

Competing products

Biosimilars in pipeline

Brand and biosimilar sales forecasts

Evaluating the Sales of Biosimilars across Various Indications:

Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency

Focus of the Analysis for Each Indication:

Historical brand sales

Brand and biosimilar sales forecasts

Indication wise breakup of molecules

Evaluating the Biosimilar Competitive Landscape:

Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars

Identifying biosimilar manufacturers and their pipelines

Understanding the Current Legislation on Biosimilars:

An insight into the Biologics Price Competition and Innovation Act

An insight into the key biosimilar issues that still remain unaddressed

Interchangeability and Substitutability

Data Exclusivity

Statutory provisions for dealing with patent litigations

Contents

1 MARKET DEFINITIONS & RESEARCH METHODOLOGY

2 EXECUTIVE SUMMARY

3 THE US BIOSIMILAR MARKET LANDSCAPE

4 US BIOSIMILAR MARKET: CURRENT EXPERIENCE

- 4.1 The Performance of Growth Hormone Biosimilars Has Been Dismal So Far
- 4.2 Pediatrics Represent the Prime Customer Base for Growth Hormones
- 4.3 Omnitrope Was Launched with an Inconvenient Delivery Device
- 4.4 Prescribing Patterns for Omnitrope
- 4.5 Uptake is Likely to Increase with the Accumulation of Post-Market Safety Data

5 US BIOSIMILAR MARKET: HOW MUCH PRICE, VOLUME & SALES EROSION WILL RESULT

- 5.1 Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars
- 5.2 The European Uptake of ESA & GCSF Biosimilars Give Us a Very Positive Outlook for the US
- 5.3 Models for Biosimilar Volume Erosion Across Various Biological Classes
- 5.4 Models for Biosimilar Price Erosion Across Various Biological Classes
- 5.5 Models for Biosimilar Sales Erosion Across Various Biological Classes

6 US BIOSIMILAR MARKET: CURRENT TRENDS & FORECAST BY DRUG

- 6.1 Growth Hormones
 - 6.1.1 Somatropin (Genotropin/Humatrope/Other HGH)
 - 6.1.1.1 Drug Overview
 - 6.1.1.2 Current Brand & Biosimilar Sales
 - 6.1.1.3 Brand & Biosimilar Forecast (2011-2020)
- 6.2 Erythropoiesis Stimulating Agents
 - 6.2.1 Epoetin Alfa (Epogen/Eporex)
 - 6.2.1.1 Drug Overview
 - 6.2.1.2 Historical Brand Sales
 - 6.2.1.3 Brand & Biosimilar Forecast (2011-2020)

6.3 Granulocyte Colony Stimulating Factor

6.3.1 Filgrastim (Neupogen)

6.3.1.1 Drug Overview

6.3.1.2 Historical Brand Sales

6.3.1.3 Brand & Biosimilar Forecast (2011-2020)

6.3.2 Pegfilgrastim (Neulasta)

6.3.2.1 Drug Overview

6.3.2.2 Historical Brand Sales

6.3.2.3 Brand & Biosimilar Forecast (2011-2020)

6.4 Insulin

6.4.1 Insulin Lispro (Humalog)

6.4.1.1 Drug Overview

6.4.1.2 Historical Brand Sales

6.4.1.3 Brand & Biosimilar Forecast (2011-2020)

6.4.2 Insulin Glargine (Lantus)

6.4.2.1 Drug Overview

6.4.2.2 Historical Brand Sales

6.4.2.3 Brand & Biosimilar Forecast (2011-2020)

6.4.3 Insulin Detemir (Levemir)

6.4.3.1 Drug Overview

6.4.3.2 Historical Brand Sales

6.4.3.3 Brand & Biosimilar Forecast (2011-2020)

6.5 Interferons

6.5.1 Interferon Beta-1A (Avonex)

6.5.1.1 Drug Overview

6.5.1.2 Historical Brand Sales

6.5.1.3 Brand & Biosimilar Forecast (2011-2020)

6.5.2 Interferon Beta-1A (Rebif)

6.5.2.1 Drug Overview

6.5.2.2 Historical Biosimilar Sales

6.5.2.3 Brand & Biosimilar Forecast (2011-2020)

6.5.3 Interferon Beta-1B (Betaferon/Betaseron)

6.5.3.1 Drug Overview

6.5.3.2 Historical Brand Sales

6.5.3.3 Brand & Biosimilar Forecast (2011-2020)

6.6 TNF Alpha & Monoclonal Antibodies (Immunology & Inflammation)

6.6.1 Etanercept (Enbrel)

6.6.1.1 Drug Overview

6.6.1.2 Historical Brand Sales

- 6.6.1.3 Brand & Biosimilar Forecast (2011-2020)
- 6.6.2 Infliximab (Remicade)
 - 6.6.2.1 Drug Overview
 - 6.6.2.2 Historical Brand Sales
 - 6.6.2.3 Brand & Biosimilar Forecast (2011-2020)
- 6.6.3 Adalimumab (Humira)
 - 6.6.3.1 Drug Overview
 - 6.6.3.2 Historical Brand Sales
 - 6.6.3.3 Brand & Biosimilar Forecast (2011-2020)
- 6.6.4 Ranibizumab (Lucentis)
 - 6.6.4.1 Drug Overview
 - 6.6.4.2 Historical Brand Sales
 - 6.6.4.3 Brand & Biosimilar Forecast (2011-2020)
- 6.6.5 Omalizumab (Xolair)
 - 6.6.5.1 Drug Overview
 - 6.6.5.2 Historical Brand Sales
 - 6.6.5.3 Brand & Biosimilar Forecast (2011-2020)
- 6.6.6 Natalizumab (Tysabri)
 - 6.6.6.1 Drug Overview
 - 6.6.6.2 Historical Brand Sales
 - 6.6.6.3 Brand & Biosimilar Forecast (2011-2020)
- 6.7 Monoclonal Antibodies (Oncology)
 - 6.7.1 Bevacizumab (Avastin)
 - 6.7.1.1 Drug Overview
 - 6.7.1.2 Historical Brand Sales
 - 6.7.1.3 Brand & Biosimilar Forecast (2011-2020)
 - 6.7.2 Trastuzumab (Herceptin)
 - 6.7.2.1 Drug Overview
 - 6.7.2.2 Historical Biosimilar Sales
 - 6.7.2.3 Brand & Biosimilar Forecast (2011-2020)
 - 6.7.3 Rituximab (Mabthera)
 - 6.7.3.1 Drug Overview
 - 6.7.3.2 Historical Biosimilar Sales
 - 6.7.3.3 Brand & Biosimilar Forecast (2011-2020)
 - 6.7.4 Cetuximab (Erbix)
 - 6.7.4.1 Drug Overview
 - 6.7.4.2 Historical Brand Sales
 - 6.7.4.3 Brand & Biosimilar Forecast (2011-2020)

7 US BIOSIMILAR MARKET: CURRENT TRENDS & FORECAST BY INDICATION

- 7.1 Immunology & Inflammation
 - 7.1.1 Current Trends & Forecast
 - 7.1.2 Biosimilar Sales Breakup by Molecule
- 7.2 Diabetes
 - 7.2.1 Current Trends & Forecast
 - 7.2.2 Biosimilar Sales Breakup by Molecule
- 7.3 Oncology
 - 7.3.1 Current Trends & Forecast
 - 7.3.2 Biosimilar Sales Breakup by Molecule
- 7.4 Blood Disorders
 - 7.4.1 Current Trends & Forecast
 - 7.4.2 Biosimilar Sales Breakup by Molecule
- 7.5 Growth Deficiency
 - 7.5.1 Current Trends & Forecast
 - 7.5.2 Biosimilar Sales Breakup by Molecule

8 COMPETITIVE LANDSCAPE

- 8.1 Branded Manufacturers: Companies Facing the Highest Amount of Biosimilar Erosion
- 8.2 Biosimilar Manufacturers: Companies Gaining the Most From Biosimilar Launches

9 BIOSIMILAR LEGISLATION IN THE US

- 9.1 The Biologics Price Competition and Innovation Act: An Insight
- 9.2 Biosimilar Issues that Still Remain Unaddressed
- 9.3 Major Issues Impacting the Business Strategies of Biological Companies
 - 9.3.1 Interchangeability & Substitutability
 - 9.3.2 Data Exclusivity
 - 9.3.3 Patent Litigation

10 KEY COMPANY PROFILES

- 10.1 Teva Pharmaceutical Industries Ltd.
- 10.2 Sandoz, Inc.
- 10.3 Hospira, Inc.
- 10.4 STADA Arzneimittel AG

10.5 Dr. Reddy's Laboratories Ltd.

10.6 Celltrion, Inc.

10.7 Bioexpress Therapeutics SA

List Of Figures

LIST OF FIGURES

Figure 1 1: Model Used to Forecast Brand and Biosimilar Sales

Figure 2 1: US: Executive Summary: Biosimilar Timeline: 2011-2020

Figure 3 1: US: Biosimilar Market (in Million US\$), 2007-2010

Figure 3 2: US: Biosimilar Timeline: 2011-2020

Figure 3 3: US: Biosimilar Market Forecast (in Million US\$), 2011-2020

Figure 4 1: US: Human Growth Hormone Market: Sales Share of Different Brands & Biosimilars (in %), 2007-2010

Figure 4 2: US: Human Growth Hormone Market: Brand & Biosimilar Patient Share (in %), 2007-2020

Figure 5 1: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars: Patient Share (in %), 2007-2010

Figure 5 2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010

Figure 5 3: US: Percentage of Physicians Expected to Prescribe ESA Biosimilars After They Have Been Launched, (in %), 2010

Figure 5 4: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010

Figure 5 5: Average Generic Volume Erosion of Molecules Based-on Complex Drug Characteristics, (in %)

Figure 5 6: Average Generic Volume Erosion Across Various Countries From Time Since First Generic Entry, (in %)

Figure 5 7: Average Generic Price Erosion of Molecules Based Upon Complex Drug Characteristics, (in %)

Figure 5 8: Average Generic Price Erosion Across Various Countries From Time Since First Generic Entry

Figure 5 9: Average Brand Price Erosion Across Various Countries From Time Since First Generic Entry

Figure 6 1: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Brand & Biosimilar Sales Share (in %), 2007-2010

Figure 6 2: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Share of Marketed Brands & Biosimilars (in %), 2007-2010

Figure 6 3: US: Somatropin (Genotropin/Humatrope/Other HGH) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 4: US: Epoetin Alfa (Epogen/Eporex) Market: Share of Marketed Brands (in %), 2007-2010

Figure 6 5: US: Epoetin Alfa (Epogen/Eporex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 6: US: Filgrastim (Neupogen) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 7: US: Pegfilgrastim (Neulasta) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 8: US: Insulin Lispro (Humalog) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 9: US: Insulin Glargine (Lantus) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 10: US: Insulin Detemir (Levemir) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 11: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 12: US: Interferon Beta-1A (Rebif) Market: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 13: US: Interferon Beta-1B (Betaferon/Betaseron) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 14: US: Etanercept (Enbrel) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 15: US: Infliximab (Remicade) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 16: US: Adalimumab (Humira) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 17: US: Ranibizumab (Lucentis) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 18 : US: Omalizumab (Xolair) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 19: US: Natalizumab (Tysabri) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 20: US: Bevacizumab (Avastin) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 21: US: Trastuzumab (Herceptin) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 22 : US: Rituximab (Mabthera) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 6 23: US: Cetuximab (Erbix) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020

Figure 7 1: US: Biosimilar Market Forecast: Share by Indication (in %), 2011-2020

Figure 7 2: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Share (in %), 2011-2020

Figure 7 3: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020

Figure 7 4: US: Diabetes Market forecast: Brand & Biosimilar Share (in %), 2011-2020

Figure 7 5: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020

Figure 7 6: US: Oncology Market Forecast: Brand & Biosimilar Share (in %), 2011-2020

Figure 7 7: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020

Figure 7 8: US: Blood Disorder Market Forecast: Brand & Biosimilar Share (in %), 2011-2020

Figure 7 9: US: Blood Disorder Biosimilar Market Forecast: Anemia & Neutropenia Sales (in %), 2011-2020

Figure 7 10: US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020

Figure 7 11: US: Growth Deficiency Market: Brand & Biosimilar Share (in %), 2007-2010

Figure 7 12: US: Growth Deficiency Market Forecast: Brand & Biosimilar Share (in %), 2011-2020

Figure 8 1: US: Innovator Company Brand Sales That Face Biosimilar Sales Erosion (in Million US\$), 2010 & 2020

List Of Tables

LIST OF TABLES

Table 1 1: US Biosimilar/Follow-On Biologics Market: Market Definition & Overview

Table 2 1: US: Executive Summary: Major Biosimilar Launches

Table 2 2: US: Executive Summary: Biosimilar Sales Forecast by Molecule (in Million US\$), 2011-2020

Table 2 3: US: Executive Summary: Biosimilar Sales Forecast by Indication (in Million US\$), 2011-2020

Table 3 1: US: Patent Expiries and Biosimilar Launch

Table 5 1: Biosimilar Vulnerability of Various Biopharmaceutical Classes

Table 5 2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010

Table 5 3: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010

Table 5 4: US: Various Studies & Assumptions for Biosimilar Volume Erosion

Table 5 5: US, Germany and UK: Biosimilar Volume Penetration by Molecule After 3 years from Launch (in %)

Table 5 6: Various Studies & Assumptions for Biosimilar Price Erosion

Table 5 7: US, Germany and UK: Biosimilar Sales Penetration by Molecule After 3 years from Launch (in %)

Table 6 1: US: Biosimilar Sales by Molecule (in Million US\$), 2007-2010

Table 6 2: US: Biosimilar Sales Forecast by Molecule (in Million US\$), 2011-2020

Table 6 3: US: Biosimilar Share Forecast by Molecule (in %), 2011-2020

Table 6 4: US: Somatropin: Brand & Biosimilar Market Overview

Table 6 5: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Brand & Biosimilar Sales/Patient Share, 2007-2010

Table 6 6: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Sales of Marketed Brands & Biosimilars (in Million US\$), 2007-2010

Table 6 7: US: Somatropin (Genotropin/Humatrope/Other HGH) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 6 8: US: Epoetin Alfa: Brand & Biosimilar Market Overview

Table 6 9: US: Epoetin Alfa (Epogen/Eprex) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 10: US: Epoetin Alfa (Epogen/Eprex) Market: Sales of Marketed Brands (in Million US\$), 2007-2010

Table 6 11: US: Epoetin Alfa (Epogen/Eprex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 6 12: US: Filgrastim: Brand & Biosimilar Market Overview

Table 6 13: US: Filgrastim (Neupogen) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 14: US: Filgrastim (Neupogen) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 6 15: US: Pegfilgrastim: Brand & Biosimilar Market Overview

Table 6 16: US: Pegfilgrastim (Neulasta) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 17: US: Pegfilgrastim (Neulasta) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 6 18: US: Insulin Lispro: Brand & Biosimilar Market Overview

Table 6 19: US: Insulin Lispro (Humalog) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 20: US: Insulin Lispro (Humalog) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 6 21: US: Insulin Glargine: Brand & Biosimilar Market Overview

Table 6 22: US: Insulin Glargine (Lantus) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 23: US: Insulin Glargine (Lantus) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 6 24: US: Insulin Detemir: Brand & Biosimilar Market Overview

Table 6 25: US: Insulin Detemir (Levemir) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 26: US: Insulin Detemir (Levemir) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 6 27: US: Interferon Beta-1A (Avonex): Brand & Biosimilar Market Overview

Table 6 28: US: Interferon Beta-1A (Avonex) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 29: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 6 30: US: Interferon Beta-1A (Rebif): Brand & Biosimilar Market Overview

Table 6 31: US: Interferon Beta-1A (Rebif) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 32: US: Interferon Beta-1A (Rebif) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 6 33: US: Interferon Beta-1B: Brand & Biosimilar Market Overview

Table 6 34: US: Interferon Beta-1B (Betaferon/Betaseron) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 35: US: Interferon Beta-1B (Betaferon/Betaseron) Market Forecast: Brand &

Biosimilar Sales/Patient Share, 2011-2020**Table 6 36: US: Etanercept: Brand & Biosimilar Market Overview****Table 6 37: US: Etanercept (Enbrel) Market: Brand Sales (in Millions US\$), 2007-2010****Table 6 38: US: Etanercept (Enbrel) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020****Table 6 39: US: Infliximab: Brand & Biosimilar Market Overview****Table 6 40: US: Infliximab (Remicade) Market: Brand Sales (in Millions US\$), 2007-2010****Table 6 41: US: Infliximab (Remicade) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020****Table 6 42: US: Adalimumab: Brand & Biosimilar Market Overview****Table 6 43: US: Adalimumab (Humira) Market: Brand Sales (in Millions US\$), 2007-2010****Table 6 44: US: Adalimumab (Humira) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020****Table 6 45: US: Ranibizumab: Brand & Biosimilar Market Overview****Table 6 46: US: Ranibizumab (Lucentis) Market: Brand Sales (in Million US\$), 2007-2010****Table 6 47: US: Ranibizumab (Lucentis) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020****Table 6 48: US: Omalizumab: Brand & Biosimilar Market Overview****Table 6 49: US: Omalizumab (Xolair) Market: Brand Sales (in Millions US\$), 2007-2010****Table 6 50: US: Omalizumab (Xolair) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020****Table 6 51: US: Natalizumab: Brand & Biosimilar Market Overview****Table 6 52: US: Natalizumab (Tysabri) Market: Brand Sales (in Millions US\$), 2007-2010****Table 6 53: US: Natalizumab (Tysabri) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020****Table 6 54: US: Bevacizumab: Brand & Biosimilar Market Overview****Table 6 55: US: Bevacizumab (Avastin) Market: Brand Sales (in Millions US\$), 2007-2010****Table 6 56: US: Bevacizumab (Avastin) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020****Table 6 57: US: Trastuzumab: Brand & Biosimilar Market Overview****Table 6 58: US: Trastuzumab (Herceptin) Market: Brand Sales (in Millions US\$), 2007-2010****Table 6 59: US: Trastuzumab (Herceptin) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020**

Table 6 60: US: Rituximab: Brand & Biosimilar Market Overview

Table 6 61: US: Rituximab (Mabthera) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 62: US: Rituximab (Mabthera) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 6 63: US: Cetuximab: Brand & Biosimilar Market Overview

Table 6 64: US: Cetuximab (Erbix) Market: Brand Sales (in Millions US\$), 2007-2010

Table 6 65: US: Cetuximab (Erbix) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020

Table 7 1: US: Biosimilars Market: Indications Assigned for Various Molecules

Table 7 2: US: Biosimilars Market: Sales by Indication (in Million US\$), 2007-2010

Table 7 3: US: Biosimilar Market Forecast: Sales by Indication (in Million US\$), 2011-2020

Table 7 4: US: Immunology & Inflammation Market: Brand Sales (in Million US\$), 2007-2010

Table 7 5: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Sales (in Million US\$), 2011-2020

Table 7 6: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US\$), 2011-2020

Table 7 7: US: Diabetes Market: Brand Sales (in Million US\$), 2007-2010

Table 7 8: US: Diabetes Market Forecast: Brand & Biosimilar Sales (in Million US\$), 2011-2020

Table 7 9: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US\$), 2011-2020

Table 7 10: US: Oncology Market: Brand Sales (in Million US\$), 2007-2010

Table 7 11: US: Oncology Market Forecast: Brand & Biosimilar Sales (in Million US\$), 2011-2020

Table 7 12: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US\$), 2011-2020

Table 7 13 : US: Blood Disorder Market: Brand Sales (in Million US\$), 2007-2010

Table 7 14 : US: Blood Disorder Market Forecast: Brand & Biosimilar Sales (in Million US\$), 2011-2020

Table 7 15 : US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US\$), 2011-2020

Table 7 16 : US: Growth Deficiency Market: Brand & Biosimilar Sales (in Million US\$), 2007-2010

Table 7 17 : US: Growth Deficiency Market Forecast: Brand & Biosimilar Sales (in Million US\$), 2011-2020

Table 8 1: US: Innovator Companies Facing the Highest Amount of Biosimilar Sales

Erosion (in Million US\$), 2010, 2013, 2016 & 2020

Table 8 2: Companies Developing Herceptin (Trastuzumab) Biosimilars

Table 8 3: Companies Developing Enbrel (Etanercept) Biosimilars

Table 8 4: Companies Developing Remicade (Infliximab) Biosimilars

Table 8 5: Companies Developing Mabthera (Rituximab) Biosimilars

Table 8 6: Companies Developing Humira (Trastuzumab) Biosimilars

Table 8 7: Companies Developing Other Biosimilars

Table 9 1: US: Overview of Biosimilar Legislations

Table 9 2: Comparison of Patent Protection and Data Exclusivity

I would like to order

Product name: Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)

Product link: <https://marketpublishers.com/r/B4354139CCAEN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B4354139CCAEN.html>